Each school year includes nine sessions totaling nine hours of professional development, with one hour of continuing education credit per month. November 20 – National Homeless Youth Awareness Month: ...

Rare disease drug developers struggle to survive in a biopharma investment market that prioritizes large patient populations. Initiatives like the Orphan Therapeutics Accelerator are attempting to ...

The Food and Drug Administration plans to drop its longtime standard of requiring two rigorous studies for new drug approvals ...

As AI drug discovery enters 2026, the industry faces a pivotal year of clinical tests, regulatory clarity, and market consolidation. Here, Dr Raminderpal Singh examines where AI is delivering ...

Development of new osteoporosis medications holds much promise. Safer osteoporosis drugs (devoid of adverse side-effects) would go a long way to rebuild patient confidence and avoid treatment inertia.

The Border Tax Is Back, and It’s Still a Terrible Idea Are We All Marxists Now? Audio By Carbonatix Capping drug companies’ prices and blocking their market access is the surest way to deter ...

How is AI-enabled imaging complementing, augmenting or otherwise impacting existing methods and decision-making?

Drug discovery, the art of identifying new molecules to develop pharmaceuticals, is a notoriously time-consuming and difficult process. Traditional techniques, like high-throughput screening, offer an ...

A new project seeking to transform the drug delivery process and take projects out of “the valley of death” between aspiration and accomplishment is getting help from La Jolla-based medical research ...

IQVIA Holdings is positioned as the indispensable data and technology backbone of the life sciences industry, far beyond a traditional CRO. Long-term revenue visibility is underpinned by a record ...

Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced formulation design, real-time dose flexibility, and cutting-edge CMC expertise ...

In the final part of his Pharma Commerce video interview, Ed Schoonveld, value and access advisor for Schoonveld Advisory and author of The Price of Global Health, previews his December column, ...